Literature DB >> 24723285

Should the indication of pneumococcal polysaccharide vaccine in children be definitively withdrawn?

Federico Martinón-Torres1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24723285      PMCID： PMC4305139          DOI： 10.1093/cid/ciu228

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  3 in total

1.  Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales.

Authors:  Shamez N Ladhani; Nick J Andrews; Pauline Waight; Ray Borrow; Mary P E Slack; Elizabeth Miller
Journal:  Clin Infect Dis       Date:  2013-12-02       Impact factor: 9.079

2.  Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.

Authors:  Sigurveig Th Sigurdardottir; Kimberly J Center; Katrin Davidsdottir; Vilhjalmur A Arason; Bjorn Hjalmarsson; Ragnheidur Elisdottir; Gunnhildur Ingolfsdottir; Robert Northington; Daniel A Scott; Ingileif Jonsdottir
Journal:  Vaccine       Date:  2013-12-02       Impact factor: 3.641

3.  Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-06-28       Impact factor: 17.586
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.